BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

$127.76 -0.02 (-0.02 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$127.78
Today's Range$127.16 - $128.43
52-Week Range$95.68 - $136.39
Volume186,613 shs
Average Volume167,134 shs
Market Capitalization$4.77 billion
P/E Ratio36.69
Dividend Yield1.01%
Beta0.75

About BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE logoBio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Debt-to-Equity Ratio0.35%
Current Ratio2.87%
Quick Ratio2.25%

Price-To-Earnings

Trailing P/E Ratio36.69
Forward P/E Ratio33.98
P/E Growth3.18

Sales & Book Value

Annual Sales$563 million
Price / Sales8.50
Cash Flow$5.06 per share
Price / Cash25.23
Book Value$25.44 per share
Price / Book5.02

Profitability

Trailing EPS$1.93
Net Income$76.08 million
Net Margins12.54%
Return on Equity14.11%
Return on Assets8.52%

Miscellaneous

Employees1,800
Outstanding Shares37,460,000

BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE declared a quarterly dividend on Tuesday, October 31st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share on Friday, November 24th. This represents a $1.28 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, November 9th. View BIO-TECHNE's Dividend History.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) released its quarterly earnings results on Tuesday, October, 31st. The biotechnology company reported $0.90 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.82 by $0.08. The biotechnology company had revenue of $144.61 million for the quarter, compared to analyst estimates of $142.37 million. BIO-TECHNE had a net margin of 12.54% and a return on equity of 14.11%. The business's revenue was up 10.7% compared to the same quarter last year. During the same period last year, the firm earned $0.84 EPS. View BIO-TECHNE's Earnings History.

When will BIO-TECHNE make its next earnings announcement?

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for BIO-TECHNE.

Where is BIO-TECHNE's stock going? Where will BIO-TECHNE's stock price be in 2017?

5 brokerages have issued twelve-month price targets for BIO-TECHNE's shares. Their forecasts range from $115.00 to $145.00. On average, they anticipate BIO-TECHNE's share price to reach $130.00 in the next year. View Analyst Ratings for BIO-TECHNE.

Who are some of BIO-TECHNE's key competitors?

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the folowing people:

  • Robert V. Baumgartner CPA, Independent Chairman of the Board
  • Charles R. Kummeth, President, Chief Executive Officer, Director
  • James T. Hippel, Chief Financial Officer, Senior Vice President
  • Brenda S. Furlow J.D., Senior Vice President, General Counsel, Secretary
  • David Eansor, Senior Vice President - Biotechnology
  • Robert Gavin, Senior Vice President-Protein Platforms
  • Kevin S. Gould, Senior Vice President-Clinical Controls
  • Joseph D. Keegan Ph.D., Director
  • Alpna Seth, Director
  • Charles A. Dinarello M.D., Independent Director

Who owns BIO-TECHNE stock?

BIO-TECHNE's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Atlanta Capital Management Co. L L C (5.20%), Neuberger Berman Group LLC (4.76%), Bamco Inc. NY (4.06%), Janus Henderson Group PLC (3.00%), Jackson Square Partners LLC (2.30%) and Royce & Associates LP (1.76%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.

Who sold BIO-TECHNE stock? Who is selling BIO-TECHNE stock?

BIO-TECHNE's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Segall Bryant & Hamill LLC, Royce & Associates LP, Janus Henderson Group PLC, Neuberger Berman Group LLC, Kornitzer Capital Management Inc. KS, Mackenzie Financial Corp and Riverbridge Partners LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE.

Who bought BIO-TECHNE stock? Who is buying BIO-TECHNE stock?

BIO-TECHNE's stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, State of Tennessee Treasury Department, Assenagon Asset Management S.A., Foundry Partners LLC, Jackson Square Partners LLC, Tygh Capital Management Inc., Public Employees Retirement Association of Colorado and Sivik Global Healthcare LLC. View Insider Buying and Selling for BIO-TECHNE.

How do I buy BIO-TECHNE stock?

Shares of BIO-TECHNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of BIO-TECHNE stock can currently be purchased for approximately $127.76.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $4.77 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $1.93 on an earnings per share basis. BIO-TECHNE employs 1,800 workers across the globe.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854.


MarketBeat Community Rating for BIO-TECHNE (TECH)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BIO-TECHNE (NASDAQ:TECH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.80
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $124.50$124.50$122.60$120.60
Price Target Upside: 4.09% downside0.59% upside0.62% upside9.87% upside

BIO-TECHNE (NASDAQ:TECH) Consensus Price Target History

Price Target History for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ:TECH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017Leerink SwannReiterated RatingBuyMediumView Rating Details
10/31/2017Deutsche BankSet Price TargetBuy$145.00N/AView Rating Details
10/24/2017CitigroupReiterated RatingBuy$125.00 -> $115.00N/AView Rating Details
7/13/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
3/27/2017Janney Montgomery ScottDowngradeBuy -> NeutralHighView Rating Details
8/18/2016Robert W. BairdBoost Price TargetOutperform$115.00 -> $116.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

BIO-TECHNE (NASDAQ:TECH) Earnings History and Estimates Chart

Earnings by Quarter for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ TECH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
10/31/2017Q1 2018$0.82$0.90$142.37 million$144.61 millionViewN/AView Earnings Details
8/8/2017Q4 2017$0.99$1.09$150.25 million$156.60 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.93$0.97$142.83 million$144.04 millionViewListenView Earnings Details
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

BIO-TECHNE (NASDAQ:TECH) Earnings Estimates

2017 EPS Consensus Estimate: $3.49
2018 EPS Consensus Estimate: $3.77
2019 EPS Consensus Estimate: $4.03
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.76$0.81$0.78
Q2 20173$0.81$0.85$0.83
Q3 20173$0.90$0.96$0.93
Q4 20173$0.93$0.98$0.95
Q1 20181$0.88$0.88$0.88
Q2 20182$0.84$0.89$0.87
Q3 20182$0.96$0.98$0.97
Q4 20182$1.02$1.09$1.06
Q1 20191$0.89$0.89$0.89
Q2 20191$0.92$0.92$0.92
Q3 20191$1.04$1.04$1.04
Q4 20191$1.18$1.18$1.18
(Data provided by Zacks Investment Research)

Dividends

BIO-TECHNE (NASDAQ:TECH) Dividend Information

Most Recent Dividend:11/24/2017
Annual Dividend:$1.28
Dividend Yield:1.00%
Payout Ratio:66.32% (Trailing 12 Months of Earnings)
34.04% (Based on This Year's Estimates)
30.84% (Based on Next Year's Estimates)
Dividend Payments by Quarter for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ:TECH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/31/2017Quarterly$0.321%11/9/201711/10/201711/24/2017
8/9/2017Quarterly$0.321.1%8/16/20178/18/20179/1/2017
5/2/2017quarterly$0.321.15%5/17/20175/19/20176/2/2017
2/7/2017quarterly$0.321.27%2/15/20172/17/20173/3/2017
11/1/2016Quarterly$0.3211/9/201611/14/201611/28/2016
8/17/2016quarterly$0.328/25/20168/29/20169/12/2016
5/3/2016quarterly$0.321.27%5/11/20165/13/20165/27/2016
2/2/2016quarterly$0.321.48%2/10/20162/12/20162/26/2016
10/29/2015quarterly$0.321.45%11/10/201511/13/201511/27/2015
8/6/2015quarterly$0.321.18%8/13/20158/17/20158/28/2015
5/5/2015quarterly$0.321.31%5/11/20155/15/20155/29/2015
2/3/2015quarterly$0.321.4%2/11/20152/13/20152/27/2015
10/30/2014quarterly$0.321.41%11/6/201411/10/201411/24/2014
8/11/2014quarterly$0.311.31%8/19/20148/21/20148/29/2014
4/28/2014quarterly$0.311.37%5/7/20145/9/20145/23/2014
2/4/2014quarterly$0.311.48%2/12/20142/14/20142/28/2014
10/31/2013quarterly$0.311.4%11/7/201311/12/201311/25/2013
8/6/2013quarterly$0.301.62%8/14/20138/16/20138/31/2013
4/30/2013quarterly$0.301.86%5/8/20135/10/20135/24/2013
2/5/2013quarterly$0.301.74%2/13/20132/15/20133/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

BIO-TECHNE (NASDAQ TECH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 97.03%
Insider Trades by Quarter for BIO-TECHNE (NASDAQ:TECH)
Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ TECH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Robert V BaumgartnerDirectorSell5,000$130.18$650,900.00View SEC Filing  
10/10/2017Roger C LucasDirectorSell100$121.96$12,196.00View SEC Filing  
9/8/2017Roger C LucasDirectorSell100$120.94$12,094.00View SEC Filing  
9/6/2017Karen A HolbrookDirectorSell1,059$121.73$128,912.07View SEC Filing  
8/10/2017Roger C LucasDirectorSell100$114.30$11,430.00View SEC Filing  
7/10/2017Roger C LucasDirectorSell100$116.86$11,686.00View SEC Filing  
6/9/2017Roger C LucasDirectorSell100$113.62$11,362.00View SEC Filing  
5/31/2017Charles A DinarelloDirectorSell5,000$111.37$556,850.00View SEC Filing  
5/25/2017Karen A HolbrookDirectorSell5,000$111.15$555,750.00View SEC Filing  
5/10/2017Roger C LucasDirectorSell100$110.59$11,059.00View SEC Filing  
4/10/2017Roger C LucasDirectorSell100$101.15$10,115.00View SEC Filing  
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.00View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.00View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.00View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.00View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.00View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.39View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.30View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.00View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.00View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.00View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.00View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.00View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.00View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.00View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.00View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.00View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.00View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.00View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.00View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.00View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BIO-TECHNE (NASDAQ TECH) News Headlines

Source:
DateHeadline
Bio-Techne (TECH) Stock Rating Lowered by BidaskClubBio-Techne (TECH) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 11 at 12:14 AM
Bio-Technes (TECH) "Buy" Rating Reaffirmed at Leerink SwannBio-Techne's (TECH) "Buy" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - December 5 at 10:34 AM
TECH Crosses Above Average Analyst TargetTECH Crosses Above Average Analyst Target
www.nasdaq.com - December 1 at 6:21 PM
Bio-Techne Corp (TECH) Given Average Rating of "Buy" by AnalystsBio-Techne Corp (TECH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 30 at 8:54 AM
Bio-Technes RNAscope® Technology Enabling Robust Gene Expression and Biomarker Analysis Advances Wide-ranging Research with over 1000 PublicationsBio-Techne's RNAscope® Technology Enabling Robust Gene Expression and Biomarker Analysis Advances Wide-ranging Research with over 1000 Publications
finance.yahoo.com - November 28 at 11:08 AM
$145.90 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter$145.90 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter
www.americanbankingnews.com - November 28 at 2:52 AM
ETFs with exposure to Bio-Techne Corp. : November 27, 2017ETFs with exposure to Bio-Techne Corp. : November 27, 2017
finance.yahoo.com - November 27 at 4:03 PM
 Brokerages Anticipate Bio-Techne Corp (TECH) to Announce $0.92 Earnings Per Share Brokerages Anticipate Bio-Techne Corp (TECH) to Announce $0.92 Earnings Per Share
www.americanbankingnews.com - November 26 at 7:28 PM
Bio-Techne Offers Updated Novus Panel Builder, Facilitating Multicolor Flow Cytometry Panel DesignBio-Techne Offers Updated Novus Panel Builder, Facilitating Multicolor Flow Cytometry Panel Design
www.prnewswire.com - November 20 at 8:11 AM
Bio-Techne Corp. :TECH-US: Earnings Analysis: Q1, 2018 By the Numbers : November 16, 2017Bio-Techne Corp. :TECH-US: Earnings Analysis: Q1, 2018 By the Numbers : November 16, 2017
finance.yahoo.com - November 18 at 9:13 AM
ETFs with exposure to Bio-Techne Corp. : November 17, 2017ETFs with exposure to Bio-Techne Corp. : November 17, 2017
finance.yahoo.com - November 18 at 9:13 AM
Bio-Techne Awards 40,000 USD Research Grant to Innovative Cancer ResearcherBio-Techne Awards 40,000 USD Research Grant to Innovative Cancer Researcher
finance.yahoo.com - November 14 at 3:49 PM
 Brokerages Expect Bio-Techne Corp (TECH) Will Post Quarterly Sales of $145.90 Million Brokerages Expect Bio-Techne Corp (TECH) Will Post Quarterly Sales of $145.90 Million
www.americanbankingnews.com - November 10 at 9:58 AM
Robust Earnings Momentum Metrics Drive Upgrade of Bio-Techne (TECH) to BuyRobust Earnings Momentum Metrics Drive Upgrade of Bio-Techne (TECH) to Buy
investorplace.com - November 9 at 3:38 PM
Featured Company News - Japanese Patent Office Issued New Patent to Alexion Pharmas Soliris; Extending Patent Protection into 2027Featured Company News - Japanese Patent Office Issued New Patent to Alexion Pharma's Soliris; Extending Patent Protection into 2027
finance.yahoo.com - November 9 at 2:31 PM
Women In Bio Announces that Alpna Seth Joins Bio-Techne’s Board of DirectorsWomen In Bio Announces that Alpna Seth Joins Bio-Techne’s Board of Directors
finance.yahoo.com - November 7 at 11:49 AM
Women In Bio Announces that Alpna Seth Joins Bio-Technes Board of DirectorsWomen In Bio Announces that Alpna Seth Joins Bio-Techne's Board of Directors
feeds.benzinga.com - November 7 at 10:07 AM
Q2 2018 EPS Estimates for Bio-Techne Corp Raised by William Blair (TECH)Q2 2018 EPS Estimates for Bio-Techne Corp Raised by William Blair (TECH)
www.americanbankingnews.com - November 6 at 11:52 AM
Bio-Techne Corp (TECH) Rating Increased to Buy at Zacks Investment ResearchBio-Techne Corp (TECH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - November 4 at 8:23 AM
Insider Selling: Bio-Techne Corp (TECH) Director Sells 5,000 Shares of StockInsider Selling: Bio-Techne Corp (TECH) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - November 3 at 5:42 PM
Bio-Techne Shows Market Leadership With Jump To 81 RS RatingBio-Techne Shows Market Leadership With Jump To 81 RS Rating
finance.yahoo.com - November 2 at 9:40 AM
Bio-Techne Corp (TECH) Plans Quarterly Dividend of $0.32Bio-Techne Corp (TECH) Plans Quarterly Dividend of $0.32
www.americanbankingnews.com - November 1 at 10:32 AM
Edited Transcript of TECH earnings conference call or presentation 31-Oct-17 1:00pm GMTEdited Transcript of TECH earnings conference call or presentation 31-Oct-17 1:00pm GMT
finance.yahoo.com - November 1 at 1:54 AM
BRIEF-Bio-Techne releases Q1 adjusted earnings per share $0.90BRIEF-Bio-Techne releases Q1 adjusted earnings per share $0.90
www.reuters.com - October 31 at 3:51 PM
Bio-Techne (TECH) Q1 2018 Results - Earnings Call TranscriptBio-Techne (TECH) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - October 31 at 3:51 PM
Deutsche Bank AG Analysts Give Bio-Techne Corp (TECH) a $145.00 Price TargetDeutsche Bank AG Analysts Give Bio-Techne Corp (TECH) a $145.00 Price Target
www.americanbankingnews.com - October 31 at 3:25 PM
Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?
finance.yahoo.com - October 31 at 10:30 AM
ETFs with exposure to Bio-Techne Corp. : October 30, 2017ETFs with exposure to Bio-Techne Corp. : October 30, 2017
finance.yahoo.com - October 31 at 10:30 AM
Bio-Techne to Host Earnings CallBio-Techne to Host Earnings Call
finance.yahoo.com - October 31 at 10:30 AM
Bio-Techne Releases First Quarter Fiscal 2018 ResultsBio-Techne Releases First Quarter Fiscal 2018 Results
finance.yahoo.com - October 31 at 10:30 AM
Bio-Techne Corp (TECH) Issues Quarterly  Earnings ResultsBio-Techne Corp (TECH) Issues Quarterly Earnings Results
www.americanbankingnews.com - October 31 at 8:56 AM
Bio-Techne To Present At The Stephens Fall Investment ConferenceBio-Techne To Present At The Stephens Fall Investment Conference
finance.yahoo.com - October 27 at 4:11 PM
Bio-Techne Adds Two New Directors to Its BoardBio-Techne Adds Two New Directors to Its Board
finance.yahoo.com - October 27 at 6:41 AM
Bio-Techne Corp (TECH) Set to Announce Earnings on TuesdayBio-Techne Corp (TECH) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 24 at 9:38 AM
Bio-Techne Corp (TECH) Expected to Post Earnings of $0.89 Per ShareBio-Techne Corp (TECH) Expected to Post Earnings of $0.89 Per Share
www.americanbankingnews.com - October 19 at 11:35 AM
Comparing Global Blood Therapeutics (GBT) and BIO-TECHNE Corp (TECH)Comparing Global Blood Therapeutics (GBT) and BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - October 17 at 4:30 PM
Bio-Techne Reaches Analyst Target PriceBio-Techne Reaches Analyst Target Price
www.nasdaq.com - October 14 at 8:33 AM
Roger C. Lucas Sells 100 Shares of Bio-Techne Corp (TECH) StockRoger C. Lucas Sells 100 Shares of Bio-Techne Corp (TECH) Stock
www.americanbankingnews.com - October 12 at 7:50 PM
Bio-Techne Corp (TECH) Raised to "Buy" at Zacks Investment ResearchBio-Techne Corp (TECH) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 1:32 PM
Bio-Techne Corp (TECH) Given Average Rating of "Buy" by BrokeragesBio-Techne Corp (TECH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 11 at 8:49 AM
ETFs with exposure to Bio-Techne Corp. : October 10, 2017ETFs with exposure to Bio-Techne Corp. : October 10, 2017
finance.yahoo.com - October 11 at 8:26 AM
Bio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial ResultsBio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial Results
finance.yahoo.com - October 11 at 8:26 AM
Bio-Techne Corp. :TECH-US: Earnings Analysis: Q4, 2017 By the Numbers : October 9, 2017Bio-Techne Corp. :TECH-US: Earnings Analysis: Q4, 2017 By the Numbers : October 9, 2017
finance.yahoo.com - October 10 at 7:26 AM
Joint Consortia Framework Awards Contract to Bio-Techne as Supplier of Research AntibodiesJoint Consortia Framework Awards Contract to Bio-Techne as Supplier of Research Antibodies
finance.yahoo.com - October 6 at 11:08 AM
Bio-Techne Corp (TECH) & Its Competitors Head-To-Head ComparisonBio-Techne Corp (TECH) & Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - October 4 at 8:36 AM
Bio-Techne's New Simple Plex Cartridge Boosts Protein SegmentBio-Techne's New Simple Plex Cartridge Boosts Protein Segment
finance.yahoo.com - October 3 at 1:26 PM
Bio-Techne Shows Rising Relative Strength; Still Shy Of Key BenchmarkBio-Techne Shows Rising Relative Strength; Still Shy Of Key Benchmark
finance.yahoo.com - October 3 at 1:26 PM
$142.75 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter$142.75 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter
www.americanbankingnews.com - October 2 at 5:18 AM
 Analysts Expect Bio-Techne Corp (TECH) Will Announce Earnings of $0.89 Per Share Analysts Expect Bio-Techne Corp (TECH) Will Announce Earnings of $0.89 Per Share
www.americanbankingnews.com - September 30 at 2:20 PM
Berkeley accelerator adds money to the mixBerkeley accelerator adds money to the mix
www.bizjournals.com - September 29 at 9:38 AM

SEC Filings

BIO-TECHNE (NASDAQ:TECH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BIO-TECHNE (NASDAQ:TECH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BIO-TECHNE (NASDAQ TECH) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.